Subtotal $0.00
Shop Now
Ozempic before and after photos online tend to show dramatic changes, but the clinical trials give a more realistic picture. In STEP 1, the main 68-week trial of semaglutide for weight management and the basis for Wegovy, average weight fell 14.9% compared with 2.4% on placebo, according to the Wegovy prescribing information. About two in three people lost at least 10% of their starting weight and about three in ten lost 20% or more, while roughly one in six did not reach 5%. Ozempic itself is approved for type 2 diabetes, not weight management, and average losses in its diabetes trials were smaller, about 3 to 6.5 kg. Weight came off gradually, reached its lowest point around week 60, and most of it returned within a year of stopping.
Peptide Labs does not sell Ozempic, Wegovy or any prescription drug, and this page shows no patient photos or testimonials. It summarizes FDA labels and published trials. For average results across every GLP-1 medicine, see our overview of GLP-1 trial results.
Key Takeaways
- STEP 1 (semaglutide as in Wegovy): average weight change of -14.9% at 68 weeks versus -2.4% on placebo.
- In that trial 83.5% lost at least 5%, 66.1% at least 10% and 30.2% at least 20% of starting weight.
- People with type 2 diabetes lost less: -9.6% on average in STEP 2.
- Ozempic's diabetes trials showed average losses of about 3 to 6.5 kg over 30 to 56 weeks.
- Loss was visible from week 4 and levelled off around week 60.
- After stopping, people in a STEP 1 extension regained about two-thirds of the weight they had lost.
What Ozempic before and after looks like in the trials
STEP 1 enrolled 1,961 adults with obesity, or with overweight plus a weight-related condition such as high blood pressure, and no diabetes. Their average age was 46, 74% were women, and the average starting weight was 105.3 kg (about 232 pounds). Everyone received counseling on a reduced-calorie diet and more physical activity, plus a weekly injection of semaglutide or placebo. The trial was funded by Novo Nordisk and published in the New England Journal of Medicine in 2021, which reported an average loss of 15.3 kg (about 34 pounds) on semaglutide versus 2.6 kg on placebo.
The table shows how many people reached each weight-loss threshold at week 68, as listed in the Wegovy label (revised June 2026). It includes STEP 2, a similar trial in adults with type 2 diabetes.
| Result at week 68 | STEP 1: semaglutide | STEP 1: placebo | STEP 2 (diabetes): semaglutide | STEP 2: placebo |
|---|---|---|---|---|
| Average weight change | -14.9% | -2.4% | -9.6% | -3.4% |
| Lost at least 5% | 83.5% | 31.1% | 67.4% | 30.2% |
| Lost at least 10% | 66.1% | 12% | 44.5% | 10.2% |
| Lost at least 15% | 47.9% | 4.8% | 25.1% | 4.3% |
| Lost at least 20% | 30.2% | 1.7% | 12.8% | 2.3% |
These label figures count everyone who was randomized, including people who stopped the medicine, with missing weights estimated statistically. Among only those weighed at week 68, the journal paper reported slightly higher shares, for example 86.4% reaching 5% and 32.0% reaching 20%. Either way, a 20% loss, the kind of change that dominates social media, was reached by a minority of participants.
Ozempic and Wegovy results: why the numbers differ
Ozempic and Wegovy contain the same molecule, semaglutide, but they are approved for different purposes. Ozempic is approved to improve blood sugar control in adults with type 2 diabetes and to lower the risk of major heart and kidney events in certain people with diabetes. Wegovy is approved for weight reduction and long-term weight maintenance, and uses a higher maintenance strength. Our comparison of Wegovy and Ozempic covers the differences in detail.
In the Ozempic label’s diabetes trials, which lasted 30 to 56 weeks, average weight change in the semaglutide groups ranged from about 3.2 to 6.4 kg (roughly 7 to 14 pounds), against 1.2 kg on placebo in the monotherapy trial. People with type 2 diabetes generally lose less weight on GLP-1 medicines, as STEP 2 shows. For a fuller answer to how much weight can you lose on Ozempic, including other trials, see our GLP-1 results overview.
Semaglutide before and after: the timeline
Semaglutide before and after changes do not happen in a few weeks. In STEP 1, weight loss was seen from the first check-in at week 4, continued for more than a year, and reached its lowest point at around week 60 before levelling off. The labels describe raising the strength gradually over the first months to limit stomach side effects, so the full effect builds slowly. Our guide to how long these medicines take to work explains the timing for blood sugar and weight.
Newer versions follow a similar pattern. In the label’s trial of Wegovy tablets, average weight change was -13.6% at 64 weeks versus -2.4% on placebo, and 27.9% lost at least 20%; see our explainer on the semaglutide tablet for weight management. A higher maintenance strength of the injection, added to the label in 2026, produced an average of -18.8% at 72 weeks compared with -15.5% on the standard strength and -3.9% on placebo.
Beyond the scale: what else changed
- Waist size. In STEP 1, waist circumference fell by an average of 13.5 cm (about 5.3 inches) on semaglutide versus 4.1 cm on placebo.
- Health measures and daily function. Blood pressure, blood sugar and blood fats improved more than on placebo, and participants reported greater gains in physical functioning.
- Body composition. The Wegovy label says semaglutide lowers body weight with greater fat mass loss than lean mass loss. In a body-scan substudy, about 38% of the weight lost was lean mass, which includes muscle, water and organs; see what the scans show about muscle.
- Face and body shape. Rapid fat loss can make the face look hollow or the buttocks look flatter. These changes reflect fat and skin changes after large weight loss rather than a unique drug effect; see changes in the face and changes in the buttocks.
Why social media before and after photos mislead
A single pair of photos cannot tell you what to expect. Common reasons they mislead:
- Selection. People post their most striking results; people who lost little rarely do. In the trials, roughly one in six on semaglutide lost less than 5%.
- Presentation. Lighting, posture, clothing, camera angle, editing and the time of day can change how a body looks without any change in weight.
- Missing context. Photos rarely show the starting weight, the time span, other medicines, surgery or major diet changes.
- Unknown product. Many posts involve compounded or online products that are not the FDA-approved medicines tested in trials; see our guide to compounded semaglutide and tirzepatide.
- Advertising rules. Under the Federal Trade Commission’s endorsement guides, an ad featuring a consumer’s result is likely to be read as showing what people generally achieve, so advertisers need evidence for that or must clearly disclose typical results.
Trials also show that not everyone stays on the medicine. In the label’s three main 68-week weight trials, 16% of people on semaglutide stopped it early, and 6.8% stopped because of side effects such as nausea, compared with 3.2% on placebo. Our guide to semaglutide side effects lists the label rates.
Why results vary from person to person
An average of about 15% hides a wide spread. Diabetes, age, other medicines that cause weight gain, sleep, eating patterns, side effects that limit how much medicine a person can tolerate, and missed injections all play a part. If progress stalls, our article on why some people lose little on semaglutide covers the common reasons, and changes to a prescription belong to the prescriber.
What happens after stopping
The after picture depends on staying on the medicine. In the STEP 1 extension, 327 participants who stopped semaglutide and the trial’s lifestyle program at week 68 had lost 17.3% on average; a year later they had regained 11.6 percentage points, about two-thirds of the loss. In STEP 4, people who were switched to placebo after 20 weeks regained 6.9% over the next 48 weeks, while those who continued lost a further 7.9%. Read more in our guide to what happens when semaglutide is stopped. For tirzepatide data, see our sibling article on Zepbound before and after results.
Frequently Asked Questions
What do realistic Ozempic before and after results look like?
In the STEP 1 weight-management trial, average weight fell 14.9% over 68 weeks versus 2.4% on placebo. About two-thirds lost at least 10% and about three in ten lost at least 20%.
How long does it take to see a difference?
In STEP 1, weight loss was measurable from week 4 and continued until about week 60, when it levelled off. Visible changes usually take months rather than weeks.
Why do people with diabetes lose less on semaglutide?
The reasons are not fully understood, but trials consistently show smaller losses. In STEP 2, adults with type 2 diabetes lost 9.6% on average versus 14.9% in STEP 1.
Are Wegovy results the same as Ozempic results?
No. Wegovy is approved for weight management and uses a higher maintenance strength. Ozempic’s diabetes trials showed average losses of about 3 to 6.5 kg.
Can I trust before and after photos online?
Be cautious. They are selected, can be staged or edited, and may involve products that are not FDA-approved. Trial averages are a more reliable guide.
Does the weight come back after stopping semaglutide?
Often, yes. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: GLP-1 for Weight Loss: What the Trials Actually Showed, How Long Does Ozempic Take to Work? Labels and Trials Explained, Ozempic Not Working? Reasons Backed by Trial and Label Data.